when will semaglutide become generic Be Available? Novo Nordisk prepares new cheaper

While the therapy did not meet its primary endpoint of progression-free survival, it showed a notable improvement in overall survival: patients receiving IGV-001 had a median overall survival of 20.3 months compared with 14.0 months in the placebo arm, representing a 6.3-month increase

Furthermore, they were people already taking these diabetes medications, and researchers tracked outcomes over time

these patients had more recent interactions, and therefore, may be less healthy than the general population receiving GLP-1s

Survodutide (BI 456906) is a GLP-1/glucagon co-agonist which has progressed to phase 3 clinical trials as treatment for obesity (SYNCHRONIZE programme)

In other words, despite producing significantly greater overall weight loss than semaglutide or tirzepatide, retatrutide did not cause a disproportionately higher percentage of muscle loss (Coskun et al., Lancet Diabetes Endocrinol , 2025)

Tesamorelin is a synthetic analogue of GRF used to increase GH and IGF-1, particularly in the context of HIV-related lipodystrophy